Geneva, Switzerland and Radnor, PA August 20, 2020 – RELIEF THERAPEUTICS Holdings SA (SIX:RLF) and NeuroRx, Inc. announce that clinical findings in the first 21 patients treated with RLF-100 (aviptadil) under FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization have been submitted by investigators at the Houston Methodist Hospital as a preprint to the SSRN server maintained by Elsevier[1]. The manuscript has been submitted for peer review to a leading scientific journal.
The Expanded Access Protocol (previously announced by Relief and NeuroRx) is designed to treat patients whose co-morbidities exclude them from enrollment in the ongoing phase 2/3 placebo-controlled trial of RLF-100. Further details can be found on www.clinicaltrials.gov NCT04453839.
Relief notes that an earlier draft of this manuscript was circulated in financial forums by unauthorized persons. Only the manuscript on the SSRN server available under the above link should be considered to represent the official findings of the study. The findings of Dr. Youssef and his team demonstrate that some critically ill patients with COVID-19 experienced substantial clinical improvement when treated with RLF-100. We await the results of the ongoing placebo-controlled trial in order to assess the magnitude of clinical effect.
https://relieftherapeutics.com/relief-therapeutics-and-neurorx-note-submission-of-clinical-results-from-21-patient-study-for-publication/
News